Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

This study tests whether adding a targeted antibody drug (nimotuzumab) to standard chemoradiation therapy helps patients with esophageal squamous cell cancer (a type of throat/food-pipe cancer) that cannot be surgically removed. These patients will have already received initial chemotherapy with or without immunotherapy. **You may be eligible if...** - You have been diagnosed with squamous cell cancer of the esophagus confirmed by biopsy - Your cancer has been assessed as stable or locally progressing after 2–4 cycles of induction chemotherapy, or surgeons have determined it cannot be removed - Your performance status and blood/organ function are within acceptable ranges **You may NOT be eligible if...** - You have another type of primary cancer - Your blood counts or organ function are too low - You have had distant spread of cancer beyond the local area Talk to your doctor to see if this trial is right for you.